FIG 7.

Sirt1 activator SRT2104 inhibits HSV-1- or exogenous cytosolic DNA-induced innate immune responses. (A) PMA-THP1 cells were treated with SRT2104 (5 μM) for 12 h and then infected with HSV-1 (MOI = 1) for 24 h. The titers of HSV-1 were determined by a standard plaque assay. Data were obtained from three independent experiments. (B) PMA-THP1 cells were treated with SRT2104 (5 μM) for 12 h and then infected with HSV-1 (MOI = 1) for 8 h. Afterward, real-time PCR analysis was performed. (C) PMA-THP1 cells were treated with SRT2104 (5 μM) for 12 h and then stimulated with HSV-1 (MOI = 1) or HSV60 (1 μg/mL) transfection. The supernatants were collected and subjected to ELISA analysis. Data were obtained from four independent experiments. (D) PMA-THP1 cells were treated with SRT2104 (5 μM) for 12 h and then infected with HSV-1 (MOI = 1) for the indicated periods. Afterward, the cells were lysed for immunoblot analysis. (E) Wild-type (WT) and Sirt1-deficient (KO) PMA-THP1 cells were treated with control DMSO or SRT2104 (5 μM) for 12 h and then infected with HSV-1 (MOI = 1) for 4 h. Afterward, real-time PCR analysis was performed. β-Actin served as a loading control in all the immunoblot assays. The data are representative of three independent experiments and are presented as means ± SDs. *, P < 0.05; **, P < 0.01; ***, P < 0.001.